How does 0A8L's PS Ratio compare to its peers?

0A8L is good value based on its Price-To-Sales Ratio (9.9x) compared to the peer average (12x).

How does 0A8L's PS Ratio compare vs other companies in the GB Biotechs Industry?

0A8L is expensive based on its Price-To-Sales Ratio (9.9x) compared to the European Biotechs industry average (7.9x).

What is 0A8L's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0A8L's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 0A8L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0A8L's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

OpGen (LSE:0A8L) - Stock Price, News & Analysis

0A8L Stock Overview

A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. More details

0A8L fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 6.5% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the UK market

+ 2 more risks

OpGen, Inc. Competitors

ProBiotix Health

OFEX:PBX

UK£10.3m

Oncimmune Holdings

AIM:ONC

UK£17.2m

Aptamer Group

AIM:APTA

UK£6.5m

OptiBiotix Health

AIM:OPTI

UK£12.2m

Price History & Performance

Summary of all time highs, changes and price drops for OpGen
Historical stock prices
Current Share Price	US$1.59
52 Week High	US$9.87
52 Week Low	US$1.42
Beta	-0.60
11 Month Change	-14.05%
3 Month Change	-24.29%
1 Year Change	-64.74%
33 Year Change	-99.51%
5 Year Change	n/a
Change since IPO	-99.69%

Recent updates

Shareholder Returns

	0A8L	GB Biotechs	GB Market
7D	-16.3%	0.3%	2.2%
1Y	-64.7%	-18.3%	8.0%

Return vs Industry: 0A8L underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0A8L underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0A8L's price volatile compared to industry and market?
0A8L volatility
0A8L Average Weekly Movement	20.3%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0A8L's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0A8L's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2001	93	John Tan	www.opgen.com

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.

OpGen, Inc. Fundamentals Summary

How do OpGen's earnings and revenue compare to its market cap?
0A8L fundamental statistics
Market cap	US$12.53m
Earnings (TTM)	-US$9.92m
Revenue (TTM)	US$1.27m

9.9x

P/S Ratio

-1.3x

P/E Ratio

Is 0A8L overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A8L income statement (TTM)
Revenue	US$1.27m
Cost of Revenue	US$1.59m
Gross Profit	-US$323.88k
Other Expenses	US$9.59m
Earnings	-US$9.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.19
Gross Margin	-25.59%
Net Profit Margin	-783.50%
Debt/Equity Ratio	0%

How did 0A8L perform over the long term?

See historical performance and comparison

0A8L Stock Overview

Risk Analysis

OpGen, Inc. Competitors

OFEX:PBX

UK£10.3m

AIM:ONC

UK£17.2m

AIM:APTA

UK£6.5m

AIM:OPTI

UK£12.2m

Price History & Performance

Recent News & Updates

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Recent updates

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

OpGen, Inc. announced delayed 10-Q filing

OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$5.92 loss in 3Q 2022)

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2020)

Shareholder Returns

Price Volatility

About the Company

OpGen, Inc. Fundamentals Summary

9.9x

-1.3x

Earnings & Revenue